Literature DB >> 25896633

Intrathecal Injection of JWH-015 Attenuates Bone Cancer Pain Via Time-Dependent Modification of Pro-inflammatory Cytokines Expression and Astrocytes Activity in Spinal Cord.

Cui'e Lu1, Yue Liu, Bei Sun, Yu'e Sun, Bailing Hou, Yu Zhang, Zhengliang Ma, Xiaoping Gu.   

Abstract

Cannabinoid receptor type 2 (CB2) agonists display potential analgesic effects in acute and neuropathic pain. However, its complex cellular and molecular mechanisms in bone cancer pain remain unclear. And less relevant reports concerned its time-dependent effects on the long-lasting modifications of behavior, spinal inflammatory cytokines levels, astrocytes activity induced by bone cancer pain. A rat model of bone cancer pain induced by intra-tibia inoculation of Walker 256 mammary gland carcinoma cells was utilized. Pain behaviors at different time points were assessed by ambulatory pain scores and paw withdrawal mechanical threshold (PWMT). Pro-inflammatory cytokines, such as interleukin (IL)-1β, IL-6, IL-18, and tumor necrosis factor alpha (TNF-α), were quantitated by Western blots. Glial activity was assessed by immunohistochemistry. Intra-tibia inoculation of Walker 256 mammary gland carcinoma cells induced progressive bone cancer pain; a long-term up-regulation of IL-1β, IL-6, IL-18, and TNF-α; and the activation of glia in spinal cord. Activation of microglia was first evident on day 4 after surgery and reached to a peak on day 7 while activation of astrocytes was on day 10. A single intrathecal injection of JWH-015 attenuated bone cancer induced spontaneous pain and mechanical allodynia, reduced the expression of pro-inflammatory cytokines, and inhibited the activity of astrocytes. All the modifications were transient and peaked at 24 h after JWH-015 administration. Furthermore, the protective effects of JWH-015 were reversed in the presence of CB2-selective antagonist AM630. Overall, our results provided evidences for the persistent participation of inflammation reaction in the progression of bone cancer pain, and demonstrated that JWH-015 reduced the expression of IL-1β, IL-6, IL-18, and TNF-α and inhibited astrocytes activation in a time-dependent manner, thereby displaying an analgesic effect.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25896633     DOI: 10.1007/s10753-015-0168-3

Source DB:  PubMed          Journal:  Inflammation        ISSN: 0360-3997            Impact factor:   4.092


  60 in total

Review 1.  CB2: a cannabinoid receptor with an identity crisis.

Authors:  Brady K Atwood; Ken Mackie
Journal:  Br J Pharmacol       Date:  2010-06       Impact factor: 8.739

2.  Efficient analysis of experimental observations.

Authors:  W J Dixon
Journal:  Annu Rev Pharmacol Toxicol       Date:  1980       Impact factor: 13.820

3.  Pharmacology of cannabinoid receptor agonists and a cyclooxygenase-2 inhibitor in rat bone tumor pain.

Authors:  Jin Hua Cui; Jin Ju; Myung Ha Yoon
Journal:  Pharmacology       Date:  2013-09-04       Impact factor: 2.547

Review 4.  Emerging drugs for neuropathic pain.

Authors:  Ian Gilron; Anthony H Dickenson
Journal:  Expert Opin Emerg Drugs       Date:  2014-05-03       Impact factor: 4.191

5.  Involvement of spinal cord nuclear factor kappaB activation in rat models of proinflammatory cytokine-mediated pain facilitation.

Authors:  Annemarie Ledeboer; Michael Gamanos; Wenmin Lai; David Martin; Steven F Maier; Linda R Watkins; Ning Quan
Journal:  Eur J Neurosci       Date:  2005-10       Impact factor: 3.386

6.  Lentiviral-mediated targeted NF-kappaB blockade in dorsal spinal cord glia attenuates sciatic nerve injury-induced neuropathic pain in the rat.

Authors:  Alice Meunier; Alban Latrémolière; Elisa Dominguez; Annie Mauborgne; Stéphanie Philippe; Michel Hamon; Jacques Mallet; Jean-Jacques Benoliel; Michel Pohl
Journal:  Mol Ther       Date:  2007-02-13       Impact factor: 11.454

7.  The role of N-methyl-D-aspartate receptor subunit NR2B in spinal cord in cancer pain.

Authors:  XiaoPing Gu; Juan Zhang; ZhengLiang Ma; JunHua Wang; XiaoFang Zhou; YanQing Jin; XiaoPing Xia; Qin Gao; FengMei Mei
Journal:  Eur J Pain       Date:  2009-10-07       Impact factor: 3.931

8.  Interleukin-18-mediated microglia/astrocyte interaction in the spinal cord enhances neuropathic pain processing after nerve injury.

Authors:  Kan Miyoshi; Koichi Obata; Takashi Kondo; Haruki Okamura; Koichi Noguchi
Journal:  J Neurosci       Date:  2008-11-26       Impact factor: 6.167

9.  Glial-cytokine-neuronal interactions underlying the mechanisms of persistent pain.

Authors:  Wei Guo; Hu Wang; Mineo Watanabe; Kohei Shimizu; Shiping Zou; Stacey C LaGraize; Feng Wei; Ronald Dubner; Ke Ren
Journal:  J Neurosci       Date:  2007-05-30       Impact factor: 6.167

10.  Impaired neuropathic pain responses in mice lacking the chemokine receptor CCR2.

Authors:  Catherine Abbadie; Jill A Lindia; Anne Marie Cumiskey; Larry B Peterson; John S Mudgett; Ellen K Bayne; Julie A DeMartino; D Euan MacIntyre; Michael J Forrest
Journal:  Proc Natl Acad Sci U S A       Date:  2003-06-13       Impact factor: 11.205

View more
  22 in total

Review 1.  Targeting Cannabinoid Receptor 2 on Peripheral Leukocytes to Attenuate Inflammatory Mechanisms Implicated in HIV-Associated Neurocognitive Disorder.

Authors:  Michael D Rizzo; Joseph E Henriquez; Lance K Blevins; Anthony Bach; Robert B Crawford; Norbert E Kaminski
Journal:  J Neuroimmune Pharmacol       Date:  2020-05-14       Impact factor: 4.147

2.  Intrathecal administration of Resolvin D1 and E1 decreases hyperalgesia in mice with bone cancer pain: Involvement of endocannabinoid signaling.

Authors:  Iryna A Khasabova; Mikhail Y Golovko; Svetlana A Golovko; Donald A Simone; Sergey G Khasabov
Journal:  Prostaglandins Other Lipid Mediat       Date:  2020-07-31       Impact factor: 3.072

3.  A Single Intrathecal or Intraperitoneal Injection of CB2 Receptor Agonist Attenuates Bone Cancer Pain and Induces a Time-Dependent Modification of GRK2.

Authors:  Cui'e Lu; Linyu Shi; Bei Sun; Yu Zhang; Bailing Hou; Yu'e Sun; Zhengliang Ma; Xiaoping Gu
Journal:  Cell Mol Neurobiol       Date:  2016-03-02       Impact factor: 5.046

4.  Glucocorticoid-Potentiated Spinal Microglia Activation Contributes to Preoperative Anxiety-Induced Postoperative Hyperalgesia.

Authors:  Rao Sun; Zhibin Zhao; Jiying Feng; Jinhua Bo; Hui Rong; Yishan Lei; Cui'e Lu; Xiaobao Zhang; Bailing Hou; Yu'e Sun; Yue Liu; Zhengliang Ma; Xiaoping Gu
Journal:  Mol Neurobiol       Date:  2016-06-23       Impact factor: 5.590

5.  The analgesic effect of rolipram is associated with the inhibition of the activation of the spinal astrocytic JNK/CCL2 pathway in bone cancer pain.

Authors:  Chi-Hua Guo; Lu Bai; Huang-Hui Wu; Jing Yang; Guo-Hong Cai; Xin Wang; Sheng-Xi Wu; Wei Ma
Journal:  Int J Mol Med       Date:  2016-09-30       Impact factor: 4.101

Review 6.  Interleukin-6: an emerging regulator of pathological pain.

Authors:  Ya-Qun Zhou; Zheng Liu; Zhi-Heng Liu; Shu-Ping Chen; Man Li; Allahverdi Shahveranov; Da-Wei Ye; Yu-Ke Tian
Journal:  J Neuroinflammation       Date:  2016-06-07       Impact factor: 8.322

Review 7.  High Times for Painful Blues: The Endocannabinoid System in Pain-Depression Comorbidity.

Authors:  Marie Fitzgibbon; David P Finn; Michelle Roche
Journal:  Int J Neuropsychopharmacol       Date:  2015-09-05       Impact factor: 5.176

8.  Inducible Lentivirus-Mediated siRNA against TLR4 Reduces Nociception in a Rat Model of Bone Cancer Pain.

Authors:  Ruirui Pan; Huiting Di; Jinming Zhang; Zhangxiang Huang; Yuming Sun; Weifeng Yu; Feixiang Wu
Journal:  Mediators Inflamm       Date:  2015-10-18       Impact factor: 4.711

9.  Breakthrough Cancer Pain Is Associated with Spinal Gap Junction Activation via Regulation of Connexin 43 in a Mouse Model.

Authors:  Xin Li; Siqing Jiang; Hui Yang; Qian Liao; Shousong Cao; Xuebin Yan; Dong Huang
Journal:  Front Cell Neurosci       Date:  2017-07-17       Impact factor: 5.505

10.  MiR-135-5p Alleviates Bone Cancer Pain by Regulating Astrocyte-Mediated Neuroinflammation in Spinal Cord through JAK2/STAT3 Signaling Pathway.

Authors:  Ming Liu; Xuefeng Cheng; Hong Yan; Jingli Chen; Caihua Liu; Zhonghui Chen
Journal:  Mol Neurobiol       Date:  2021-06-27       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.